skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Informa pharma logo

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

PharmaLogo
Search Icon Report storeRecommendationsProduct loginProductLogin
Global Search Configuration

As the aging population in the US, UK and Europe increases, cases of multiple have increased as well, bring new therapies and questions about the future of care. This webinar provides a comprehensive look at the disease and treatments including the new launches that are transforming clinical practice, the relative value of multiple myeloma regimens, and the evolution of the multiple myeloma market.

 

Beginning with the current access levers used by payers and a comparison of US and five major European markets, you’ll learn the key factors in European payers’ assessment of multiple myeloma treatments, the significant changes we are seeing in the US oncology market, and why payers have begun imposing cost-control strategies such as ICER and other value frameworks to evaluate cost-effectiveness.

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907
  • Japan            : +81 3-6273-4257

Or email us your inquiry, so we can provide you the best possible customer service:
pharma@informa.com
General enquiry

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now